Gyre Therapeutics/$GYRE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Ticker

$GYRE
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

579

ISIN

US4037831033
Website
www.gyretx.com

GYRE Metrics

BasicAdvanced
$679M
335.08
$0.02
-
-

Bulls say / Bears say

Gyre Therapeutics' Hydronidone met the primary endpoint in a pivotal Phase 3 trial for CHB-associated liver fibrosis in China, with 52.85% of treated patients achieving ≥1-stage fibrosis regression compared to 29.84% for placebo (P=0.0002). This success positions the company to submit a New Drug Application to China's NMPA in Q3 2025. (stocktitan.net)
The company successfully raised approximately $20 million through a public offering priced at $9.00 per share, providing critical capital to advance its Phase 2 clinical trial of F351 for MASH-associated liver fibrosis in the United States. (gyretx.com)
Institutional investors, such as Barclays PLC, have increased their stake in Gyre Therapeutics, indicating confidence in the company's future prospects. (defenseworld.net)
Gyre Therapeutics reported Q1 2025 revenue of $22.1 million, a decline from $27.2 million in Q1 2024, indicating potential challenges in maintaining revenue growth. (stocktitan.net)
The company's stock price experienced a significant drop of 22.57% following the announcement of positive Phase 3 trial results, suggesting market skepticism or profit-taking behavior. (stocktitan.net)
Insider selling activity, including the sale of 2,000 shares by President Songjiang Ma, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

GYRE News

AllArticlesVideos
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

GlobeNewsWire·1 month ago
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·2 months ago
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GYRE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs